An emerging class of new therapeutics targeting TGF , Activin, and BMP ligands in pulmonary arterial hypertension

Abstract excerpt

Pulmonary arterial hypertension (PAH) is an often fatal condition, the primary pathology of which involves loss of pulmonary vascular perfusion due to progressive aberrant vessel remodeling. The reduced capacity of the pulmonary circulation places increasing strain on the right ventricle of the heart, leading to death by heart failure. Currently, licensed therapies are primarily vasodilators, which have increased...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiovascular Issues in Pregnancy
• Share to Pulmonary Hypertension Research and Treatments